Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasted to Post Q2 2024 Earnings of ($0.38) Per Share

Janux Therapeutics, Inc. (NASDAQ:JANXFree Report) – Stock analysts at HC Wainwright decreased their Q2 2024 EPS estimates for shares of Janux Therapeutics in a note issued to investors on Monday, May 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.38) per share for the quarter, down from their prior forecast of ($0.35). HC Wainwright currently has a “Buy” rating and a $63.00 target price on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.44) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.72) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($0.23) EPS.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.05. The firm had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%.

A number of other brokerages have also recently commented on JANX. Wedbush increased their price target on shares of Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, May 9th. Jonestrading started coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They issued a “buy” rating and a $70.00 price target on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Finally, BTIG Research assumed coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $69.50.

Read Our Latest Stock Analysis on Janux Therapeutics

Janux Therapeutics Trading Down 0.9 %

NASDAQ JANX opened at $47.48 on Thursday. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60. The stock has a 50 day moving average of $45.65 and a 200-day moving average of $23.88. The company has a market cap of $2.46 billion, a PE ratio of -38.92 and a beta of 3.87.

Institutional Trading of Janux Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its holdings in shares of Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after buying an additional 2,685 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Janux Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock valued at $152,000 after purchasing an additional 3,602 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Janux Therapeutics by 82.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after purchasing an additional 4,400 shares during the period. ProShare Advisors LLC acquired a new position in shares of Janux Therapeutics during the 1st quarter worth approximately $251,000. Finally, Lester Murray Antman dba SimplyRich bought a new position in shares of Janux Therapeutics during the first quarter worth approximately $300,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Read More

Earnings History and Estimates for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.